Bayer

Key Takeaways • Extended dosing reduced the frequency of injections by 50%, enhancing patient convenience. • EYLEA HD maintained vision gains across central, branch, and hemiretinal...

key TakeawaysFinerenone may offer significant blood pressure management benefits in heart failure patients. The drug could potentially reduce the frequency of outpatient worsening...

Key TakeawaysBayer's focus on AI integration indicates a strategic move towards automating and enhancing diagnostic processes in radiology. The introduction of lower-dose contrast...

Key TakeawaysThe MEDRAD Centargo system addresses the critical need for efficiency in radiology departments. Its automation features help tackle the increasing workload of...

Key TakeawaysSignificant reduction in carbon footprint and environmental impact. Improved sustainability without additional cost. Commitment to maintaining product quality and safety. Collaboration with...

Bayer has taken a significant step forward in the treatment of heart disease by securing an exclusive licensing agreement with Dewpoint Therapeutics. This collaboration,...

In an ambitious move to push the boundaries of women's health, Bayer has secured a partnership with Impli, a start-up renowned for its cutting-edge...

Key TakeawaysBayer, in collaboration with Orion, has submitted darolutamide for approval by the European Medicines Agency (EMA), aiming to expand its use in...

Key TakeawaysBayer and MOMA Therapeutics enter a collaboration to develop a small molecule oncology program, enhancing Bayer’s precision oncology portfolio. MOMA will receive...

Key TakeawaysBayer’s New Drug Application for elinzanetant, targeting moderate to severe vasomotor symptoms (VMS) in menopausal women, has been accepted by the U.S....

Key TakeawaysBlueRock’s bemdaneprocel continues to show a favorable safety profile at 24 months in the Phase 1 exPDite trial for Parkinson's disease. Early...

Key TakeawaysBayer submits an application for darolutamide in combination with ADT for metastatic hormone-sensitive prostate cancer (mHSPC). The Phase III ARANOTE trial showed...

Key TakeawaysThe intrauterine device, including Mirena, offers long-term contraception with a failure rate of less than 1%, lasting between three to five years,...

Key TakeawaysDarolutamide plus ADT reduced the risk by 46% in mHSPC patients compared to placebo plus ADT. The safety of darolutamide was consistent...

Key TakeawaysA post-hoc analysis from the PULSAR trial revealed that Eylea™ 8 mg provided rapid and sustained control of retinal fluid, particularly when...